Truist Financial Corp acquired a new position in Amedisys, Inc. (NASDAQ:AMED – Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 2,784 shares of the health services provider’s stock, valued at approximately $205,000.
A number of other hedge funds and other institutional investors have also recently modified their holdings of AMED. BlackRock Inc. lifted its holdings in shares of Amedisys by 3.7% in the 1st quarter. BlackRock Inc. now owns 3,896,785 shares of the health services provider’s stock worth $671,378,000 after acquiring an additional 138,484 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Amedisys by 0.3% in the third quarter. Vanguard Group Inc. now owns 3,042,027 shares of the health services provider’s stock worth $294,438,000 after buying an additional 10,457 shares during the period. Wellington Management Group LLP increased its holdings in shares of Amedisys by 3.5% in the first quarter. Wellington Management Group LLP now owns 1,875,274 shares of the health services provider’s stock worth $323,092,000 after buying an additional 62,863 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of Amedisys by 3.4% in the fourth quarter. JPMorgan Chase & Co. now owns 1,759,870 shares of the health services provider’s stock worth $147,020,000 after buying an additional 58,365 shares during the period. Finally, Mackenzie Financial Corp increased its holdings in shares of Amedisys by 3.8% in the fourth quarter. Mackenzie Financial Corp now owns 1,041,142 shares of the health services provider’s stock worth $86,977,000 after buying an additional 38,517 shares during the period. 95.70% of the stock is currently owned by hedge funds and other institutional investors.
Amedisys Price Performance
AMED opened at $93.79 on Tuesday. The stock has a fifty day simple moving average of $91.63 and a two-hundred day simple moving average of $85.40. The company has a current ratio of 0.92, a quick ratio of 0.92 and a debt-to-equity ratio of 0.35. The company has a market cap of $3.06 billion, a price-to-earnings ratio of 1,340.05, a price-to-earnings-growth ratio of 2.54 and a beta of 1.04. Amedisys, Inc. has a 12-month low of $69.36 and a 12-month high of $126.81.
Amedisys (NASDAQ:AMED – Get Free Report) last posted its quarterly earnings data on Wednesday, July 26th. The health services provider reported $1.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.09 by $0.28. The business had revenue of $552.97 million during the quarter, compared to the consensus estimate of $568.18 million. Amedisys had a return on equity of 14.00% and a net margin of 0.10%. The firm’s quarterly revenue was down .9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.47 earnings per share. Research analysts predict that Amedisys, Inc. will post 4.42 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several research analysts have recently commented on the company. Benchmark downgraded Amedisys from a “buy” rating to a “hold” rating in a report on Tuesday, June 27th. TD Cowen raised their target price on shares of Amedisys from $84.00 to $101.00 and gave the stock a “market perform” rating in a report on Monday, July 31st. StockNews.com started coverage on shares of Amedisys in a report on Monday. They set a “buy” rating for the company. Barclays increased their target price on shares of Amedisys from $88.00 to $101.00 in a report on Tuesday, June 27th. Finally, Cantor Fitzgerald increased their target price on shares of Amedisys from $91.00 to $100.00 in a report on Tuesday, June 6th. Ten equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, Amedisys presently has a consensus rating of “Hold” and an average target price of $109.60.
Check Out Our Latest Stock Report on Amedisys
Amedisys Company Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through four segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
Read More
Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys, Inc. (NASDAQ:AMED – Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Amedisys, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Amedisys wasn’t on the list.
While Amedisys currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
Do you expect the global demand for energy to shrink?! If not, it’s time to take a look at how energy stocks can play a part in your portfolio.
Source: marketbeat.com
